A long-term, extended treatment study of aripiprazole in pediatric patients with schizophrenia
Phase 3
- Conditions
- Schizophrenia
- Registration Number
- JPRN-jRCT2080221113
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
1) Patients with a diagnosis of schizophrenia according to DSM-IV-TR
2) Male and female patients aged 13-17 years
3) Patients completing the 031-09-003 study
Exclusion Criteria
1) Patients who have a diagnosis of any other disease except schizophrenia, according to DSM-IV-TR
2) Patients who fall under a contraindication listed in the ABILIFY package insert
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of aripiprazole in treating pediatric schizophrenia?
How does aripiprazole compare to other antipsychotics in long-term pediatric schizophrenia management?
What biomarkers predict response to aripiprazole in pediatric schizophrenia patients?
What are the long-term adverse events associated with aripiprazole in pediatric populations?
Are there combination therapies involving aripiprazole for pediatric schizophrenia treatment?